Mental and Emotional Impairment in Patients With Hepatitis C is Related to Lower Work Productivity

Psychosomatics

Volumn 57, Issue 1, 2016, Pages 82-88

  Younossi, Issah ^a,b   Weinstein, Ali ^a,b   Stepanova, Maria ^b   Hunt, Sharon ^b   Younossi, Zobair M ^a,c  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b Center for Outcomes Research in Liver Diseases   (United States)

^c BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABSENTEEISM; ADULT; ARTICLE; CHRONIC LIVER DISEASE QUESTIONNAIRE HEPATITIS C VIRUS; CONTROLLED STUDY; DEPRESSION; EMOTIONAL STABILITY; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE ASSESSMENT; MENTAL HEALTH; PRESENTEEISM; PRODUCTIVITY; RETROSPECTIVE STUDY; SHORT FORM 36; ANXIETY; COHORT ANALYSIS; COMORBIDITY; EMPLOYMENT; FATIGUE; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; MIDDLE AGED; PHASE 3 CLINICAL TRIAL (TOPIC); PSYCHOLOGY; QUESTIONNAIRE; RISK FACTOR; SEX DIFFERENCE; WORK;

ANTIVIRUS AGENT;

ABSENTEEISM; ADULT; ANTIVIRAL AGENTS; ANXIETY; CLINICAL TRIALS, PHASE III AS TOPIC; COHORT STUDIES; COMORBIDITY; DEPRESSION; EFFICIENCY; EMPLOYMENT; FATIGUE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SURVEYS AND QUESTIONNAIRES; WORK;

EID: 84958818988     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1016/j.psym.2015.10.005     Document Type: Article

References (27)

1. Davis G.L., Alter M.J., El-Serag H., Poynard T., Jennings L.W. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010, 138:513-521.
2. Younossi Z.M., Kanwal F., Saab S., et al. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther 2014, 39(5):518-531.
3. Younossi Z., Henry L. The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Dig Liver Dis 2014, 46(5 Suppl):S186-S196.
4. Escorpizo R. Understanding work productivity and its application to work-related musculoskeletal disorders. Int J Ind Ergon 2008, 38(3-4):291-297.
5. Mchutchison J.G., Ware J.E., Bayliss M.S., et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001, 34(1):140-147.
6. Younossi Z., Henry L. Systematic review: patient-reported outcomes in chronic hepatitis C-the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther 2015, 41(6):497-520.
7. John-Baptiste A.A., Tomlinson G., Hsu P.C., et al. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol 2009, 104(10):2439-2448.
8. DiBonaventura M., Wagner J.S., Yuan Y., L'Italien G., Langley P., Ray K.W. The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities. J Med Econ 2011, 14:253-261.
9. Younossi Z.M., Stepanova M., Henry L., et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol 2014, 60(4):741-747.
10. Younossi Z.M., Stepanova M., Zeuzem S., et al. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study. J Hepatol 2014, 61(2):228-234.
11. Younossi Z.M., Stepanova M., Afdhal N., et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol 2015, 63(2):337-345.
12. Zdilar D., Franco-Bronson K., Buchler N., Locala J.A., Younossi Z.M. Hepatitis C interferon alfa, and depression. Hepatology 2000, 31(6):1207-1211.
13. Schaefer M., Sarkar R., Knop V., et al. Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med 2012, 157(2):94-103.
14. Younossi Z.M., Jiang Y., Smith N.J., Stepanova M., Beckerman R. Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: insights from a work productivity economic model from the United States. Hepatology 2015, 61(5):1471-1478.
15. Younossi Z., Brown A., Buti M., et al. Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five european countries. J Viral Hepatitis 2015, [in press], http://dx.doi.org/10.1111/jvh.12483.
16. Lawitz E., Mangia A., Wyles D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013, 368(20):1878-1887.
17. Jacobson I.M., Gordon S.C., Kowdley K.V., et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013, 368(20):1867-1877.
18. Afdhal N., Zeuzem S., Kwo P., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014, 370(20):1889-1898.
19. Afdhal N., Reddy K.R., Nelson D.R., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014, 370(16):1483-1493.
20. Zeuzem S., Dusheiko G.M., Salupere R., et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014, 370(21):1993-2001.
21. Kowdley K.V., Gordon S.C., Reddy K.R., et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014, 370(20):1879-1888.
22. Younossi Z.M., Stepanova M., Pol S., Bronowicki J.P., Carrieri M.P., Bourlière M. The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study. Liver Int 2015, 10.1111/liv.12886.
23. Younossi Z.M., Stepanova M., Sulkowski M., et al. Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV: the impact on patient-reported outcomes. J Infect Dis 2015, 212(3):367-377.
24. Younossi Z.M., Guyatt G., Kiwi M., Boparai N., King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999, 45:295-300.
25. Hays R.D., Morales L.S. The RAND-36 measure of health-related quality of life. Ann Med 2001, 33(5):350-357.
26. Cella D.F., Tulsky D.S., Gray G., et al. The Functional Assessment of Cancer Therapy (FACT) scale: development and validation of the general measure. J Clin Oncol 1993, 11(3):570-579.
27. Reilly M.C., Zbrozek A.S., Dukes E.M. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 1993, 4:353-365.